aripiprazole has been researched along with er-086526 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HS; Kim, JY; Lee, BM; Tae, IH; Yoon, S | 1 |
| Jiang, C; Kim, HS; Kim, JR; Lee, JS; Lee, SH; Park, JH; Park, JW; Yoon, S | 1 |
2 other study(ies) available for aripiprazole and er-086526
| Article | Year |
|---|---|
Low Doses of the Anti-psychotic Drug Aripiprazole Have Strong P-gp-inhibitory Activity and Sensitize Anti-mitotic Drug-resistant Cancer Cells.
Topics: Antimitotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Survival; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Furans; Gene Expression Regulation, Neoplastic; Humans; Ketones; Neoplasms; Vincristine | 2018 |
A Low Dose of Aripiprazole Has the Strongest Sensitization Effect Among 19 Repositioned Bipolar Drugs in P-gp-overexpressing Drug-resistant Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Apoptosis; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Furans; G2 Phase Cell Cycle Checkpoints; Humans; Ketones; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Vincristine | 2021 |